20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
TransMedics Group Inc (TMDX) operates in the MEDICAL DEVICES industry and is headquartered in Andover, United States with about 898 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, TMDX reported $605M in revenue and $190M in net income.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Interactive charts & full statements → Open the TMDX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $668M | $605M | $442M | $242M | $93M | $30M | $26M | $24M | $13M | $8M | $6M | — |
| Gross Profit | $392M | $363M | $262M | $154M | $65M | $21M | $17M | $14M | $6M | $2M | $1M | — |
| Gross Margin % | 58.7% | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | 64.9% | 58.7% | 44.0% | 27.8% | 12.3% | — |
| Operating Income (EBIT) | $82M | $109M | $37M | ($29M) | ($31M) | ($39M) | ($26M) | ($30M) | ($20M) | ($20M) | ($23M) | ($18M) |
| Operating Margin % | 12.2% | 17.9% | 8.5% | -11.9% | -33.6% | -130.3% | -102.9% | -125.4% | -155.5% | -265.8% | -370.2% | — |
| Net Income | $152M | $190M | $35M | ($25M) | ($36M) | ($44M) | ($29M) | ($34M) | ($24M) | ($21M) | ($24M) | ($18M) |
| Net Margin % | 22.7% | 31.4% | 8.0% | -10.4% | -38.8% | -146.1% | -112.1% | -142.1% | -182.5% | -271.0% | -387.6% | — |
| EBITDA | $120M | $148M | $70M | ($8M) | ($29M) | ($38M) | ($23M) | ($28M) | ($20M) | ($19M) | ($23M) | — |
| Earnings Per Share (EPS) | $3.73 | $4.69 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 | $-1.23 | $-1.44 | $-1.66 | — |
| Shares Outstanding (M) | 41M | 41M | 35M | 33M | 30M | 28M | 25M | 14M | 19M | 14M | 14M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $190M | $174M | $161M | $144M | $157M | $144M | $122M | $109M |
| Gross Profit | $113M | $101M | $93M | $85M | $97M | $88M | $72M | $61M |
| Gross Margin % | 59.6% | 58.2% | 58.1% | 58.8% | 61.4% | 61.5% | 59.2% | 55.9% |
| Operating Income (EBIT) | $24M | $13M | $21M | $23M | $37M | $27M | $9M | $4M |
| Operating Margin % | 12.5% | 7.6% | 13.2% | 16.2% | 23.2% | 19.1% | 7.1% | 3.6% |
| Net Income | $15M | $7M | $105M | $24M | $35M | $26M | $7M | $4M |
| Net Margin % | 7.7% | 4.2% | 65.5% | 16.9% | 22.2% | 17.9% | 5.6% | 3.9% |
| EBITDA | $27M | $28M | $32M | $33M | $46M | $36M | $16M | $13M |
| Earnings Per Share (EPS) | $0.36 | $0.20 | $2.57 | $0.60 | $0.86 | $0.64 | $0.19 | $0.12 |
| Shares Outstanding (M) | 41M | 36M | 41M | 41M | 41M | 40M | 35M | 36M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $146M | $193M | $49M | ($13M) | ($46M) | ($29M) | ($30M) | ($32M) | ($26M) | ($23M) | ($24M) | ($16M) |
| Capital Expenditures (CapEx) | $67M | $59M | $130M | $179M | $12M | $4M | $0M | $0M | $0M | $0M | $1M | $1M |
| Free Cash Flow (FCF) | $79M | $134M | ($81M) | ($192M) | ($58M) | ($32M) | ($31M) | ($32M) | ($26M) | ($23M) | ($26M) | ($17M) |
| FCF Margin % | 11.8% | 22.1% | -18.3% | -79.5% | -61.8% | -107.0% | -119.8% | -137.5% | -202.8% | -304.0% | -412.1% | — |
| Dividends Paid | — | — | — | $51M | — | — | $0M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $17M | $25M | $35M | $70M | $92M | ($3M) | $20M | $7M |
| Capital Expenditures (CapEx) | $7M | $37M | $16M | $8M | $9M | $27M | $14M | $48M |
| Free Cash Flow (FCF) | $10M | ($12M) | $19M | $62M | $83M | ($30M) | $6M | ($41M) |
| FCF Margin % | 5.4% | -7.0% | 11.8% | 43.1% | 52.4% | -20.8% | 5.0% | -38.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B | $1.1B | $804M | $706M | $277M | $135M | $152M | $105M | $42M | $37M | $58M | $15M |
| Cash & Cash Equivalents | $473M | $488M | $337M | $395M | $201M | $26M | $25M | $20M | $20M | $12M | $10M | $9M |
| Total Liabilities | $946M | $595M | $575M | $569M | $90M | $67M | $48M | $51M | $47M | $206M | $19M | $6M |
| Total Debt (Short + Long-Term) | $518M | $516M | $512M | $508M | $60M | $44M | $35M | $34M | $34M | $9M | $8M | $1M |
| Total Shareholders' Equity | $518M | $473M | $229M | $137M | $187M | $68M | $104M | $55M | ($5M) | ($169M) | $39M | $9M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TMDX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms